ArticleAnnals of African medicine2026
Vildagliptin and its Association with Bullous Pemphigoid.
Article in Annals of African medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractBullous pemphigoid (BP) is an autoimmune subepidermal blistering disease usually seen among the elderly and in conditions like stroke and dementia. It has been associated with various trigger factors and has an incidence of 0.2-3 per 1 lakh with an increase in recent times. Out of the various known triggers, drugs play a major role. Gliptins, a common group of antidiabetic medications used for the control of blood glucose levels routinely among type 2 diabetes mellitus patients, have common adverse reactions like headache, weakness, and nausea with rare presentations of skin lesions. We report three cases of elderly diabetics who were on vildagliptin for routine diabetic control, who further developed blistering disease. On evaluation of the skin lesions, a diagnosis of BP was made and confirmed with the help of direct immunofluorescence test. Routine symptomatic management and topical steroids had no role to play in the improvement of symptoms, which led to the suspicion of drug-induced BP. Patients had significantly improved since the discontinuation of vildagliptin with complete resolution over a period. Thus, these case reports help us understand the association of vildagliptin and BP, which was previously not well understood. Considering the prevalence of type 2 diabetes mellitus in India and extensive use of various antidiabetic drugs, complete understanding of adverse reactions helps and guides physicians regarding treatment choices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.